Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

BACKGROUND: Treatment options have been historically limited for cisplatin-ineligible patients with advanced urothelial carcinoma (UC). Given the need for alternatives to platinum-based chemotherapy, including non-chemotherapy regimens for patients with both impaired renal function and borderline fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Tomi, Hahn, Noah M, Sonpavde, Guru, Albany, Constantine, MacVicar, Gary R, Hauke, Ralph, Fleming, Mark, Gourdin, Theodore, Jana, Bagi, Oh, William K, Taik, Patricia, Wang, Huan, Varadarajan, Ajay Ramakrishnan, Uzilov, Andrew, Galsky, Matthew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177111/
https://www.ncbi.nlm.nih.gov/pubmed/35438782
http://dx.doi.org/10.1093/oncolo/oyab075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177111/
https://www.ncbi.nlm.nih.gov/pubmed/35438782
http://dx.doi.org/10.1093/oncolo/oyab075

Ejemplares similares